Timothy A. Springer, Ph.D.    Founder; Board of Directors; Co-chair, Scientific Advisory Board   Timothy A Springer, Ph.D. is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. He is a world leader in structural biology and immunology. He is also a founder and private investor in biopharmaceutical ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

Timothy A. Springer, Ph.D.

Founder; Board of Directors; Co-chair, Scientific Advisory Board

Timothy A Springer, Ph.D. is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. He is a world leader in structural biology and immunology. He is also a founder and private investor in biopharmaceutical ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

  Andrew Kruse, Ph.D.    Co-Founder; Co-chair, Scientific Advisory Board   Andrew Kruse, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab studies the molecular basis of membrane protein signaling important in human health and disease using biophysical techniques and structural biology. Andrew was selected for the 2016 Forbes “30 under 30” list, and is the recipient of notable awards including an NIH Director’s Early Independence Award and a Sloan Research Fellowship. He is a founder of Ab Initio Biotherapeutics.   

Andrew Kruse, Ph.D.

Co-Founder; Co-chair, Scientific Advisory Board

Andrew Kruse, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab studies the molecular basis of membrane protein signaling important in human health and disease using biophysical techniques and structural biology. Andrew was selected for the 2016 Forbes “30 under 30” list, and is the recipient of notable awards including an NIH Director’s Early Independence Award and a Sloan Research Fellowship. He is a founder of Ab Initio Biotherapeutics.

 

  Joseph Jardine, Ph.D.    Head of Antibody Discovery    

Joseph Jardine, Ph.D.

Head of Antibody Discovery

 

 
 
  Suzanne Monahan    Treasurer    

Suzanne Monahan

Treasurer

 

  Viet Q. Le, Ph.D.    Director of Operations  

Viet Q. Le, Ph.D.

Director of Operations 

  Margaret Nielsen    Operations Administrator

Margaret Nielsen

Operations Administrator